8-K: Select Medical Holdings Reports Strong Q4 and Full Year 2023 Results, Issues Positive 2024 Outlook

Select Medical Holdings Corporation announced significant increases in revenue, net income, and adjusted EBITDA for the fourth quarter and full year ended December 31, 2023, driven by growth across all segments.

Summary

• Select Medical Holdings Corporation reported a 4.9% increase in revenue to $1,658.9 million for Q4 2023, compared to $1,581.5 million in Q4 2022.
• Income from operations for Q4 2023 rose by 31.5% to $114.3 million, up from $86.9 million in the same quarter of the previous year.
• Net income for Q4 2023 saw a 63.9% increase, reaching $61.8 million compared to $37.7 million in Q4 2022.
• Adjusted EBITDA for Q4 2023 increased by 20.9% to $180.1 million, compared to $148.9 million in the prior year's quarter.
• Earnings per common share for Q4 2023 were $0.36, a 63.6% increase from $0.22 in Q4 2022.
• For the full year 2023, revenue increased by 5.2% to $6,664.1 million from $6,333.5 million in 2022.
• Full year 2023 income from operations grew by 37.6% to $554.9 million, compared to $403.3 million in the previous year.
• Net income for 2023 increased by 51.4% to $299.7 million, up from $198.0 million in 2022.
• Adjusted EBITDA for the full year 2023 rose by 24.8% to $807.4 million, compared to $646.9 million in 2022.
• Earnings per common share for 2023 were $1.91, a 54.9% increase from $1.23 in 2022, while adjusted earnings per common share were $1.99, up 61.8% from $1.23.
• The company declared a cash dividend of $0.125 per share, payable on March 13, 2024, to shareholders of record as of March 1, 2024.

Sentiment

Score: 9

Explanation: The document reflects a very positive sentiment due to strong financial performance, growth across all segments, a positive 2024 outlook, and a declared dividend.

Positives

• The company experienced growth across all its operating segments.
• Significant increases in revenue, net income, and Adjusted EBITDA were reported for both Q4 and the full year.
• The company has a strong market position as one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States.
• The board declared a cash dividend of $0.125 per share.
• The company issued a positive business outlook for 2024, projecting continued growth in revenue and Adjusted EBITDA.

Negatives

• The company experienced a decrease in occupancy rates in its critical illness recovery hospitals.
• Revenue per visit decreased slightly in the outpatient rehabilitation segment.

Risks

• Changes in government reimbursement and payment policies could negatively impact revenue and profitability.
• Adverse economic conditions, including inflation, could increase operating costs.
• Shortages of qualified healthcare professionals could limit the ability to staff facilities and increase labor costs.
• Public health threats, such as pandemics, could negatively impact patient volumes, revenues, and increase operating costs.
• Failure to maintain Medicare certifications could lead to a decline in revenue and profitability.
• Competition may limit growth and result in decreased revenue and profitability.
• Potential security breaches of information technology systems could result in legal and reputational harm.

Future Outlook

Select Medical expects 2024 revenue to be between $6.9 billion and $7.1 billion, Adjusted EBITDA to be between $830 million and $880 million, and fully diluted earnings per share to be between $1.88 and $2.18.

Industry Context

This announcement reflects a positive trend in the healthcare industry, particularly in post-acute care and rehabilitation services, as demand continues to grow. Select Medical's performance indicates a strong recovery and adaptation to the evolving healthcare landscape.

Comparison to Industry Standards

• Select Medical's revenue growth of 5.2% in 2023 is competitive within the post-acute care industry.
• Compared to Encompass Health, a major competitor in the rehabilitation hospital segment, Select Medical's Adjusted EBITDA margin of 22.6% in this segment is slightly lower than Encompass Health's margin, which has historically been around 20-24%.
• In the outpatient rehabilitation segment, Select Medical's performance is strong, with an Adjusted EBITDA margin of 9.4%, which is competitive with other major players like U.S. Physical Therapy, which typically reports margins in the low double digits.
• Select Medical's Concentra segment, focusing on occupational health, shows a robust Adjusted EBITDA margin of 19.7%, outperforming some industry benchmarks in this specialized area.

Stakeholder Impact

• Shareholders may benefit from the declared dividend and the positive outlook for 2024.
• Employees may benefit from the company's growth and stability.
• Customers and suppliers are likely to see continued or improved service levels due to the company's strong financial position.

Next Steps

• Payment of the declared cash dividend on March 13, 2024.
• Continued execution of the business strategy to achieve the projected 2024 outlook.

Key Dates

Keywords

healthcare, critical illness recovery, rehabilitation, outpatient, occupational health, Concentra, financial results, earnings, revenue, Adjusted EBITDA, dividend, business outlook